{"name":"Provectus Biopharmaceuticals","slug":"provectus","ticker":"PVCT","exchange":"OTC","domain":"provectusbio.com","description":"Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and blood cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for ","hq":"Knoxville, TN","founded":0,"employees":"6","ceo":"Dominic Rodrigues","sector":"Oncology / Dermatology","stockPrice":0.06,"stockChange":0.01,"stockChangePercent":20,"marketCap":"$24M","metrics":{"revenue":336108,"revenueGrowth":-100,"grossMargin":0,"rdSpend":1897276,"netIncome":-5430851,"cash":251291,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"PV-10 patent cliff ($0.0B at risk)","drug":"PV-10","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-14","type":"regulatory","headline":"Provectus Biopharmaceuticals Announces FDA Clearance of IND for PV-10 in Combination with Pembrolizumab","summary":"The FDA cleared the Investigational New Drug (IND) application for PV-10 in combination with pembrolizumab for the treatment of melanoma.","drugName":"PV-10","sentiment":"positive"},{"date":"2022-03-31","type":"earnings","headline":"Provectus Biopharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"The company reported a net loss of $3.3 million for the fourth quarter and $14.1 million for the full year 2021.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"trial","source":"The Manila Times","summary":"Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment - Th","headline":"Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOUDFzWXk2RE9QZnozaW8tRHJ1eVY3NnN5X3lnQ25wTTN5elNpMU5lYllPSVM3bEtCWGU2WUJMMDFteUd0RDJNdEZleEdzTk5JaXA1S1RaOHV0YXF0YnJxVGF2R0VnaUhmdkVQWHhDcGxLdGNTVWNodjBKc21sSVVkRGFkaGZvQ0xDSUNDZzNkcW94QXRhTV91U2VlSS1taWI2U1I5cHA2QXNkTVpodDRsQ09TTURSSTBVN2F4eGdxS0dwZ0Rfa292dkNKMURSelNuNkJhVzF1NUFIV0VXdF84OHRGSGpfM29DeEZtRks1MA?oc=5","date":"2026-03-26","type":"patent","source":"Minichart","summary":"Provectus Biopharmaceuticals Patents and Immunotherapy Pipeline: Rose Bengal Sodium and Halogenated Xanthenes Overview - Minichart","headline":"Provectus Biopharmaceuticals Patents and Immunotherapy Pipeline: Rose Bengal Sodium and Halogenated Xanthenes Overview","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOU0laOHpxWU1yQlJoQkhIenIwTmZBOGprdGRvc3FWYmpadG4yQ1F5WXJ2M2hXUmtMSFg3ZTN6TjNmTE5JbTcwM2V6Q0VkZmFpd0tmenRTQUh5SmlfaUxROWNvZV9Lb0QzbTFIdUhZYnpyY2Z1elhpTFI1dmxCVjdNRk9RS1J4Qkt2Q0hTdW9vaVFCa2ViX3g3d3hJSlAyTE9ZOENDRDg4bWIzTnFWWVZOb2FKRWl1Vy1QWFJoZDZPZnJ3R3Fz?oc=5","date":"2026-03-20","type":"pipeline","source":"Stock Titan","summary":"PVCT (PVCT) CEO converts 8% note and Series D-1 preferred into common stock - Stock Titan","headline":"PVCT (PVCT) CEO converts 8% note and Series D-1 preferred into common stock","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOVGhBUXB1OTBjUG5kTTdISkxWQWZHQnFISWxYSldGWXNGT1dOM01ZbmRFc2Z3b0prWEVneXItdVdIRkpPQkRUb0o3X0pxek8ycjM3YW5Ob0ZWaHktRDhkTG5HQ2EwU25sRG15aXNOY3lzd2t5TVE1cV9tYXpWUEVpRHo3VldOMWNXTF95dEtweFVycXZZWTV1UWhGay02WXZMRFpCVzYzSkw4aTdBT0NUdmh2VkhnWFduRkNkdHJ6QQ?oc=5","date":"2024-12-11","type":"pipeline","source":"Stock Titan","summary":"Provectus Launches VisiRose: Groundbreaking Eye Infection Treatment Venture with University of Miami - Stock Titan","headline":"Provectus Launches VisiRose: Groundbreaking Eye Infection Treatment Venture with University of Miami","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNSE9KTmpDdC1ObTZpYkI2TUJpNkNITHNUbHJULWx6TEVIdHNQZWlzTUpOa1RjbkMyTGNOYVE3eWZCUU1YSlVIdEVJUGQxd2RZQXA1Vm1DTkhqYXpMTmdhYTUyS3pPY3dGZE9DOUJFM1ExTWRZcGZVTFZxRlgzN3QwVTlMVURaWmhqZm9jRXk2ZzA0aGNnSGpUaFVBRGV4T0oyWUFaOHRPUXVBeEdhLVFLcW4zeUxMLWU1akswTHlNSnpaSHN0ZTVDNVRTdUR3Z0dKY1AxYS0tNTlDZUZHN0F3?oc=5","date":"2024-10-10","type":"earnings","source":"GlobeNewswire","summary":"Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewswire","headline":"Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBQZE1FS0oxWmo0WnAtUkU5b3dNOUFNUkN3d2YyT3ZGOUpVWUV5Szg1VndwX2ZpUmI1S3lHbktHcXM5V0lsYzRlczZnQmdBcFVEajZQVjB4c2t0SHM?oc=5","date":"2017-11-13","type":"pipeline","source":"MarketBeat","summary":"Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis - MarketBeat","headline":"Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNQl85OTNIZTRVdF9zQUtjazZlaDkxenExdC1zWWRRSmp2RjVoNzVNdlpzbWFsc2pLQ1d0cmlFTmdmSlREdU53R0tXbTY5RHl4SV83MFdvdVlOMldYbFA2QUJhR3IwcGJKdGlHNXlpLWNxUEI4LXUzeU1TNExYT3doN1pPQzVfTkFsS0pBekhaR2d1dnQ2Zm9rc1Fuem5kN00xRzJ6OC11eUtQS3JrNS1vZXpfeG41aVNuc0toOGxKX1pNb0taTmROLUt3MHFzdw?oc=5","date":"2017-02-24","type":"pipeline","source":"PR Newswire","summary":"Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline - PR Newswire","headline":"Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNSHpoLUxBVkFTd0wxZzdoUDk3V0NjT214d3dIbkkwMElKYkl0R0E0QmtXcmJNTFhBVEd3VExJM2Y5RHRMd19vRlFBT2FUbGtpOUcwdmd5NWFqSWNxdE5lNDg1SE5aRF9lQnlrQ01oUzdPREdHWWpvNXVDcVVqeU1hNjFUcWpfSHZ1RWZYQlRDSmpaRHVfb2VoV0Rn?oc=5","date":"2017-01-06","type":"pipeline","source":"Knoxville News Sentinel","summary":"Provectus fires interim CEO - Knoxville News Sentinel","headline":"Provectus fires interim CEO","sentiment":"neutral"}],"patents":[{"drugName":"PV-10","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["Oncology","Dermatology"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":0,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"},{"value":0,"period":"2013-12-31"},{"value":0,"period":"2012-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1897276,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5430851,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":697502,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.06,"previousClose":0.05,"fiftyTwoWeekHigh":0.1,"fiftyTwoWeekLow":0.04,"fiftyTwoWeekRange":"0.038 - 0.105","fiftyDayAverage":0.05,"twoHundredDayAverage":0.07,"beta":0.74,"enterpriseValue":26736546,"forwardPE":0,"priceToBook":-3.8,"priceToSales":71.27,"enterpriseToRevenue":79.55,"enterpriseToEbitda":-5.52,"pegRatio":0,"ebitda":-4842406,"ebitdaMargin":0,"freeCashflow":-1336186,"operatingCashflow":-3325991,"totalDebt":2978697,"debtToEquity":0,"currentRatio":0.08,"returnOnAssets":-355.4,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.8,"institutionHeldPercent":0,"sharesOutstanding":420279879,"floatShares":387951951,"sharesShort":1821793,"shortRatio":0.47,"shortPercentOfFloat":0.8,"epsTrailing":-0.01,"epsForward":0,"revenuePerShare":0,"bookValue":-0.01,"officers":[{"age":72,"name":"Mr. Edward V. Pershing CPA","title":"CEO & Executive Chairman of Board"},{"age":56,"name":"Mr. Dominic  Rodrigues C.F.A.","title":"President & Executive Vice Chairman of the Board"},{"age":62,"name":"Dr. Eric A. Wachter Ph.D.","title":"Co-Founder & CTO"},{"age":58,"name":"Ms. Heather  Raines CPA","title":"Chief Financial Officer"}],"industry":"Biotechnology","irWebsite":"http://www.pvct.com/investor.html","website":"https://www.provectusbio.com","phone":"866 594 5999"}}